Media Mentions
2011
“Seed Capital: Beyond Angels And VC”
Life Science Leader, January 2011
Paul DeStefano said about the trend of venture funding that “the United States is seeing more tranches than in the past.” Mr. DeStafano noted that “foundations are applying their [venture] funds differently than in the past,” making larger, but fewer, grants. He added that one of his life science clients just received a family foundation grant that funds all clinical trials up to $50 million.
Paul R. DeStefano, Life Sciences & Medical Products, Life Sciences - Corporate
2010
Paul DeStefano discussed the current initial public offering (IPO) environment for biotech and life sciences companies in a January 18 Boston Business Journal story. He noted that the industry has become more stratified and that more individualized criteria are being used to evaluate the IPO opportunities for medical device, therapeutics and other life science companies. By contrast, Mr. DeStefano said, “There used to be literally a checklist. If you had validation from one corporate partnership and, let’s say, a license to Japanese rights for the lead drug, you could count on an IPO of at least $90 million to $120 million.”
Paul R. DeStefano, Life Sciences & Medical Products
Paul DeStefano was mentioned in a January 4 National Law Journal feature on significant new law firm lateral hires. Mr. Stefano joined McDermott’s Menlo Park office as a member of the Health Industry Advisory and the Life Sciences & Medical Devices Practice Groups. He will counsel companies in the biotech-pharmaceutical sector on strategic planning, company formation, financing and operations.
Paul R. DeStefano, Health, Life Sciences & Medical Products
2009
Paul DeStefano was quoted in a December 28 Daily Journal story that reviewed the possible effect of health reform legislation on business combinations in the health care industry. He noted that reform bills have had little effect on mergers and acquisitions involving large pharmaceutical companies, mainly because those deals take too long to respond to rapidly changing legislative developments. “The cycle on product development is so long, so uncertain and so expensive, you can’t turn that ship based on a change made today,” Mr. DeStefano said.
Paul R. DeStefano, Health, Life Sciences & Medical Products Litigation, Life Sciences - Corporate, Life Sciences - Health
Paul DeStefano was cited by Biotech Business Week on December 14 for joining McDermott’s Silicon Valley office as a partner. Calling Mr. De Stefano “one of the nation’s elite attorneys in the biotech industry,” the article noted that he will provide guidance on the formation, financing and operations of companies in the biotech-pharmaceutical sector.
Paul R. DeStefano, Health, Life Sciences & Medical Products
Paul De Stefano was mentioned in numerous media outlets on December 2 and 3 as he joined the Health Industry Practice Group and Life Sciences & Medical Devices practice at McDermott’s Silicon Valley office. Mr. De Stefano will focus on strategic planning and legal representation in the formation, financing and operation of biotech and pharmaceutical companies. Coverage appeared in (among others) Intellectual Property Today, BusinessWeek.com, Bizz.Yahoo.com, Law360, National Law Journal, Law.com, USA Today, The Recorder, LawFuel.com and Biovalley.
